205 related articles for article (PubMed ID: 24781752)
1. Loss of locus coeruleus noradrenergic neurons alters the inflammatory response to LPS in substantia nigra but does not affect nigral cell loss.
Iravani MM; Sadeghian M; Rose S; Jenner P
J Neural Transm (Vienna); 2014 Dec; 121(12):1493-505. PubMed ID: 24781752
[TBL] [Abstract][Full Text] [Related]
2. The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation.
Iravani MM; Leung CC; Sadeghian M; Haddon CO; Rose S; Jenner P
Eur J Neurosci; 2005 Jul; 22(2):317-30. PubMed ID: 16045485
[TBL] [Abstract][Full Text] [Related]
3. Vagus nerve stimulation improves locomotion and neuronal populations in a model of Parkinson's disease.
Farrand AQ; Helke KL; Gregory RA; Gooz M; Hinson VK; Boger HA
Brain Stimul; 2017; 10(6):1045-1054. PubMed ID: 28918943
[TBL] [Abstract][Full Text] [Related]
4. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration.
Iravani MM; Kashefi K; Mander P; Rose S; Jenner P
Neuroscience; 2002; 110(1):49-58. PubMed ID: 11882372
[TBL] [Abstract][Full Text] [Related]
5. Lesion of the locus coeruleus aggravates dopaminergic neuron degeneration by modulating microglial function in mouse models of Parkinson׳s disease.
Yao N; Wu Y; Zhou Y; Ju L; Liu Y; Ju R; Duan D; Xu Q
Brain Res; 2015 Nov; 1625():255-74. PubMed ID: 26342895
[TBL] [Abstract][Full Text] [Related]
6. Increased osteopontin expression following intranigral lipopolysaccharide injection in the rat.
Iczkiewicz J; Rose S; Jenner P
Eur J Neurosci; 2005 Apr; 21(7):1911-20. PubMed ID: 15869484
[TBL] [Abstract][Full Text] [Related]
7. Fluoxetine prevents LPS-induced degeneration of nigral dopaminergic neurons by inhibiting microglia-mediated oxidative stress.
Chung ES; Chung YC; Bok E; Baik HH; Park ES; Park JY; Yoon SH; Jin BK
Brain Res; 2010 Dec; 1363():143-50. PubMed ID: 20858471
[TBL] [Abstract][Full Text] [Related]
8. Thrombin-induced microglial activation contributes to the degeneration of nigral dopaminergic neurons in vivo.
Huang CF; Li G; Ma R; Sun SG; Chen JG
Neurosci Bull; 2008 Apr; 24(2):66-72. PubMed ID: 18369384
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin prevents lipopolysaccharide-induced neurodegeneration in the rat substantia nigra by inhibiting the activation of microglia.
Bai L; Zhang X; Li X; Liu N; Lou F; Ma H; Luo X; Ren Y
Mol Med Rep; 2015 Jul; 12(1):1002-8. PubMed ID: 25777539
[TBL] [Abstract][Full Text] [Related]
10. Involvement of astroglial fibroblast growth factor-2 and microglia in the nigral 6-OHDA parkinsonism and a possible role of glucocorticoid hormone on the glial mediated local trophism and wound repair.
Silva C; Fuxe K; Chadi G
J Neural Transm Suppl; 2009; (73):185-202. PubMed ID: 20411778
[TBL] [Abstract][Full Text] [Related]
11. Thrombin-induced microglial activation produces degeneration of nigral dopaminergic neurons in vivo.
Choi SH; Joe EH; Kim SU; Jin BK
J Neurosci; 2003 Jul; 23(13):5877-86. PubMed ID: 12843292
[TBL] [Abstract][Full Text] [Related]
12. GPER activation is effective in protecting against inflammation-induced nigral dopaminergic loss and motor function impairment.
Mendes-Oliveira J; Lopes Campos F; Videira RA; Baltazar G
Brain Behav Immun; 2017 Aug; 64():296-307. PubMed ID: 28450223
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats.
Srinivasan J; Schmidt WJ
Eur J Neurosci; 2003 Jun; 17(12):2586-92. PubMed ID: 12823465
[TBL] [Abstract][Full Text] [Related]
14. Osteopontin expression in activated glial cells following mechanical- or toxin-induced nigral dopaminergic cell loss.
Iczkiewicz J; Rose S; Jenner P
Exp Neurol; 2007 Sep; 207(1):95-106. PubMed ID: 17643430
[TBL] [Abstract][Full Text] [Related]
15. Noradrenergic depletion potentiates beta -amyloid-induced cortical inflammation: implications for Alzheimer's disease.
Heneka MT; Galea E; Gavriluyk V; Dumitrescu-Ozimek L; Daeschner J; O'Banion MK; Weinberg G; Klockgether T; Feinstein DL
J Neurosci; 2002 Apr; 22(7):2434-42. PubMed ID: 11923407
[TBL] [Abstract][Full Text] [Related]
16. L-alpha-aminoadipic acid restricts dopaminergic neurodegeneration and motor deficits in an inflammatory model of Parkinson's disease in male rats.
O'Neill E; Chiara Goisis R; Haverty R; Harkin A
J Neurosci Res; 2019 Jul; 97(7):804-816. PubMed ID: 30924171
[TBL] [Abstract][Full Text] [Related]
17. Noradrenergic inputs from locus coeruleus to posterior ventral tegmental area are essential to support ethanol reinforcement.
Shelkar GP; Kumar S; Singru PS; Subhedar NK; Kokare DM
Addict Biol; 2017 Mar; 22(2):291-302. PubMed ID: 26549324
[TBL] [Abstract][Full Text] [Related]
18. Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory response.
Iravani MM; Sadeghian M; Leung CC; Tel BC; Rose S; Schapira AH; Jenner P
Exp Neurol; 2008 Aug; 212(2):522-31. PubMed ID: 18571649
[TBL] [Abstract][Full Text] [Related]
19. Apocyanin, a Microglial NADPH Oxidase Inhibitor Prevents Dopaminergic Neuronal Degeneration in Lipopolysaccharide-Induced Parkinson's Disease Model.
Sharma N; Nehru B
Mol Neurobiol; 2016 Jul; 53(5):3326-3337. PubMed ID: 26081143
[TBL] [Abstract][Full Text] [Related]
20. Noradrenaline is crucial for the substantia nigra dopaminergic cell maintenance.
Af Bjerkén S; Stenmark Persson R; Barkander A; Karalija N; Pelegrina-Hidalgo N; Gerhardt GA; Virel A; Strömberg I
Neurochem Int; 2019 Dec; 131():104551. PubMed ID: 31542295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
